Format

Send to

Choose Destination
Antiviral Res. 2016 Sep;133:85-94. doi: 10.1016/j.antiviral.2016.07.007. Epub 2016 Jul 21.

A randomized, double-blind, placebo-controlled trial evaluating the safety of early oseltamivir treatment among children 0-9 years of age hospitalized with influenza in El Salvador and Panama.

Author information

1
Influenza Division, Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA. Electronic address: fdawood@cdc.gov.
2
Centro de Estudios en Salud, Universidad del Valle de Guatemala, Guatemala City, Guatemala.
3
Gorgas Memorial Institute for Health Studies, Panama City, Panama.
4
Hospital San Juan De Dios, Santa Ana, El Salvador.
5
Hospital Materno Infantil José Domingo De Obaldía, David, Panama.
6
Hospital Del Niño, Panama City, Panama.
7
Hospital De Especialidades Pediátricas Omar Torrijos, Panama City, Panama.
8
Hospital San Juan De Dios, San Miguel, El Salvador.
9
Influenza Division, Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA.
10
CDC-Central American Regional Office, San Salvador, El Salvador.

Abstract

BACKGROUND:

Oseltamivir reduces symptom duration among children with uncomplicated influenza, but few data exist on treatment efficacy and tolerability among hospitalized children, particularly among infants aged <1 year. We evaluated tolerability and efficacy of oseltamivir treatment of children aged 0-9 years hospitalized with influenza.

METHODS:

We conducted a double-blind, randomized, placebo-controlled trial at tertiary care hospitals in El Salvador and Panama. Primary outcomes were length of hospitalization and increased work of breathing. Children were eligible if hospitalized <7 days after symptom onset with cough or sore throat plus tachypnea. Children were randomized 1:1 to receive oseltamivir or placebo; had swabs collected at enrollment for influenza RT-PCR testing; were assessed at enrollment and every 12 h for work of breathing; and were followed for adverse events through 7 days after discharge. Analyses were intention-to-treat.

RESULTS:

Overall, 683 children were randomized (oseltamivir, n = 341, placebo n = 342). Fifty-three percent were aged <1 year and 30 had influenza (oseltamivir, n = 19; placebo, n = 11). The study was terminated early after enrollment of 21% of the sample size due to lower than anticipated participant accrual. Using Kaplan-Meier analysis, there was no significant difference in median length of hospitalization (3 days, IQR 2-4 vs. 5 days, IQR 3-7, p = 0.22) and increased work of breathing (36 h, IQR 24-72 vs. 96 h, IQR 13-108, p = 0.14) between oseltamivir versus placebo recipients. There was no difference in adverse events between groups.

CONCLUSION:

Oseltamivir treatment was well tolerated among hospitalized children, including among infants aged <1 year.

KEYWORDS:

Antiviral agents; Children; Hospitalized; Human; Influenza; Oseltamivir

PMID:
27451343
DOI:
10.1016/j.antiviral.2016.07.007
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center